Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-6714

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-6714). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906714)

Losartan Potassium 25 mg film-coated tablets packaging label from A-S Medication Solutions. The label shows the product name, dosage strength, quantity of 90 tablets, storage instructions to keep at 68 to 77 degrees F, and includes a QR code and lot number information.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients reaching the primary endpoint over a study period of 66 months for Losartan Potassium and Atenolol. The graph shows a steady increase in the event rate for both treatments, with Losartan Potassium consistently having a lower rate. The chart includes an annotation noting an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between atenolol (dotted line) and losartan potassium (solid line). The graph shows adjusted risk reduction data, with losartan potassium associated with a 25% risk reduction (p=0.001). The x-axis represents study months and the y-axis represents percent of patients with stroke.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' showing hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol. The chart compares event rates for primary composite and stroke (fatal/non-fatal) outcomes across subgroups defined by age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease. The horizontal axis ranges from 0.3 to 3, indicating favorability toward either Losartan Potassium or Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A Kaplan-Meier survival curve chart comparing the percentage of patients with an event over 48 months between Losartan Potassium and Placebo groups. The solid line represents Losartan Potassium, and the dashed line represents Placebo, illustrating a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium showing its detailed molecular framework including the potassium ion (K+). The diagram depicts various rings and functional groups characteristic of Losartan Potassium, an oral film-coated tablet active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.